title: Topical halobetasol propionate in the treatment of plaque psoriasis: a review.
abstract: Halobetasol propionate (HP) 0.5% ointment and cream are class I topical corticosteroids. We review the efficacy and tolerability of HP for treatment of plaque psoriasis in the English language literature. The efficacy of HP ointment and cream is consistently superior to other super-potent topical corticosteroids. Local adverse events associated with topical HP are similar to those experienced with other super-potent corticosteroids. Combination therapy with calcipotriene (calcipotriol) and tazarotene appears to be superior to monotherapy with topical HP.
authors.affiliation: Department of Dermatology, Baylor College of Medicine, Houston, Texas 77030, USA.
authors.forename: Allison M
authors.initials: AM
authors.lastname: Rivera
authors.forename: Sylvia
authors.initials: S
authors.lastname: Hsu
mesh_terms: D000287:Administration, Topical; D002990:Clobetasol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: C064466:halobetasol; D002990:Clobetasol